PMID- 10955798
OWN - NLM
STAT- MEDLINE
DCOM- 20001228
LR  - 20181130
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 6
IP  - 8
DP  - 2000 Aug
TI  - Potential role of microvessel density in predicting radiosensitivity of T1 and T2 
      stage laryngeal squamous cell carcinoma treated with radiotherapy.
PG  - 3159-65
AB  - Curative radiotherapy is the first choice of therapy for T1 and T2 stage 
      laryngeal squamous cell carcinoma (LSCC) patients to preserve their phonation. 
      Patients with recurrent tumors who undergo salvage surgery require prolonged 
      nasal feeding. Therefore, clinical interest has been focused on elucidating a 
      predictive factor indicating which tumors are likely to be radiosensitive before 
      radiotherapy. We analyzed the relations between radiosensitivity and 
      clinicopathological factors (gender, tumor location, histological factors, and 
      clinical tumor-node-metastasis stage), expression of apoptosis-related proteins 
      (p53, bax, bcl-2), apoptotic index using the terminal 
      deoxynucleotidyltransferase-mediated nick end labeling method, expression of cell 
      proliferation-related proteins (Ki-67-labeling index and epidermal growth factor 
      receptor overexpression) and microvessel density (MVD, vessels/field = 0.391 mm2) 
      in biopsy specimens from 31 LSCC patients given radiotherapy (total radiotherapy 
      dose of 52-70 Gy over 4-6.5 weeks). Univariate analysis revealed that tumors with 
      a high MVD (> or =35 vessels/field) showed better radiosensitivity than those 
      with a low MVD (<35 vessels/field, P = 0.008) and that a high Ki-67-labeling 
      index (> or =40%) was weakly associated with radiosensitivity (P = 0.056). 
      Multivariate analysis and Kaplan-Meier analysis showed that MVD alone had 
      significant predictive power for radiosensitivity in T1 and T2 stage LSCCs after 
      radiotherapy (P = 0.012, 0.0003, respectively). No significant association 
      between clinicopathological factors, or of overexpression of p53, bax, bcl-2, 
      epidermal growth factor receptor, or apoptotic index, with radiosensitivity was 
      found. These results indicate that MVD is a potentially useful clinical factor 
      predicting radiosensitivity for patients with early stage LSCCs before treatment.
FAU - Kamijo, T
AU  - Kamijo T
AD  - Pathology, Division, National Cancer Center Research Institute East, Chiba, 
      Japan.
FAU - Yokose, T
AU  - Yokose T
FAU - Hasebe, T
AU  - Hasebe T
FAU - Yonou, H
AU  - Yonou H
FAU - Sasaki, S
AU  - Sasaki S
FAU - Hayashi, R
AU  - Hayashi R
FAU - Ebihara, S
AU  - Ebihara S
FAU - Miyahara, H
AU  - Miyahara H
FAU - Hosoi, H
AU  - Hosoi H
FAU - Ochiai, A
AU  - Ochiai A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (BAX protein, human)
RN  - 0 (CD68 antigen, human)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (bcl-2-Associated X Protein)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/biosynthesis
MH  - Antigens, Differentiation, Myelomonocytic/biosynthesis
MH  - Apoptosis/physiology
MH  - Carcinoma, Squamous Cell/*blood supply/metabolism/*radiotherapy
MH  - ErbB Receptors/biosynthesis
MH  - Female
MH  - Humans
MH  - Ki-67 Antigen/biosynthesis
MH  - Laryngeal Neoplasms/*blood supply/metabolism/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - Neovascularization, Pathologic/*physiopathology
MH  - Predictive Value of Tests
MH  - Proto-Oncogene Proteins/biosynthesis
MH  - Proto-Oncogene Proteins c-bcl-2/biosynthesis
MH  - Radiation Tolerance/*physiology
MH  - Survival Analysis
MH  - Tumor Suppressor Protein p53/biosynthesis
MH  - bcl-2-Associated X Protein
EDAT- 2000/08/24 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/24 11:00
PHST- 2000/08/24 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/24 11:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 2000 Aug;6(8):3159-65.